Recently, it was reported that high levels of NKCC1 expression predict poor clinical outcomes for lung adenocarcinoma patients and an epidermal growth factor receptor (EGFR)‐mutated subgroup (Sun et al., 2016). The gene discussed is SLC12A2; the disease is lung adenocarcinoma.